Which Pharmaceutical Stock is a Better Buy? By StockNews

Which Pharmaceutical Stock is a Better Buy? By StockNews


© Reuters. Merck vs. Sanofi: Which Pharmaceutical Stock is a Better Buy?

While the pharmaceutical industry’s upside potential based on its role in saving many lives from the deadly coronavirus virus is gradually diminishing, the continuing efforts of pharma companies in finding cures for critical diseases should keep driving the industry’s growth, with rising demand from an aging population. Despite huge industry competition, recent developments made by Merck (MRK) and Sanofi (NASDAQ:) are likely to boost their growth substantially. But let’s find out which of these stocks is a better buy now.Merck & Co., Inc. (MRK) offers health solutions through its prescription medicines, vaccines, biologic therapies and consumer care products. The company operates through two segments—Pharmaceutical and Animal Health. Its products are marketed directly and through its joint ventures to drug wholesalers and retailers, hospitals, government agencies and managed health care providers.

Sanofi (SNY) is a healthcare company based in France that researches, develops, manufactures, and markets therapeutic solutions internationally. The company operates through three segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. It also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs.

Because COVID-19 is almost under control in several countries, the pharmaceutical industry, which garnered significant attention because of its role in fighting the virus, may have little additional upside to offer investors based on COVID-19 related products and solutions. However, the continuing efforts of pharma companies in finding cures for other critical diseases should keep driving the industry’s growth. Consequently, the global pharmaceuticals market is expected to grow at an 8% CAGR to hit $1.70 trillion by 2025.

Continue reading on StockNews

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

Leave a comment

Send a Comment

Your email address will not be published.

Enter text shown below: